A JAK inhibitor, filgotinib has selectivity for a subtype JAK1 of the enzyme, which is why Gilead and Galapagos believe it would have a better safety profile than less selective JAK inhibitors, such as Pfizer’s Xeljanz ( tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq ( upadacitinib), which are on the market.
【 在 tlexander (Bird) 的大作中提到: 】 : Gilead的JAK1抑制剂用于治疗RA被FDA给拒了，原因是担心对精子产生有副作用。 : A JAK inhibitor, filgotinib has selectivity for a subtype JAK1 of the enzyme : , which is why Gilead and Galapagos believe it would have a better safety : profile than less selective JAK inhibitors, such as Pfizer’s Xeljanz ( : tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq ( : upadacitinib), which are on the market.
Gilead的JAK1抑制剂用于治疗RA被FDA给拒了，原因是担心对精子产生有副作用。
A JAK inhibitor, filgotinib has selectivity for a subtype JAK1 of the enzyme, which is why Gilead and Galapagos believe it would have a better safety
profile than less selective JAK inhibitors, such as Pfizer’s Xeljanz (
tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (
upadacitinib), which are on the market.
描述不准确，Filgotinib的三期导致有testicular cancer。我估计gilead最后还是会
重新file的，加上一个black box warning。
【 在 tlexander (Bird) 的大作中提到: 】
: Gilead的JAK1抑制剂用于治疗RA被FDA给拒了，原因是担心对精子产生有副作用。
: A JAK inhibitor, filgotinib has selectivity for a subtype JAK1 of the
enzyme
: , which is why Gilead and Galapagos believe it would have a better safety : profile than less selective JAK inhibitors, such as Pfizer’s Xeljanz (
: tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (
: upadacitinib), which are on the market.